文献速递慢性肾脏病肾血管病与高血压

肌肉生长抑制素及其抑制在慢性肾脏病中的作用

Emerging role of myostatin and its inhibition in the setting of chronic kidney disease.
PubMed 文献 · Kidney Int · 2018-12-28

本综述总结了肌肉生长抑制素(MSTN)/激活素系统激活促进肌肉蛋白降解导致消耗的机制,及其在慢性肾脏病(CKD)血管病变中的潜在作用。临床研究提示双重阻断ActRII受体可能更有效,但MSTN靶向治疗不能替代体力活动和营养补充。

要点

  • MSTN/激活素系统激活促进肌肉蛋白降解,增加CKD患者病残率和死亡率。
  • MSTN/激活素参与CKD血管加速动脉粥样硬化和血管钙化,抑制可能有益。
  • MSTN靶向治疗不应替代体力活动和营养补充。

核心结论

  • MSTN/激活素系统是CKD消耗和血管病变的重要机制,其抑制可能改善肌肉萎缩并控制血管并发症。

研究设计与样本

  • 综述,总结MSTN/激活素通路在CKD中的作用及临床前和临床研究证据。

主要发现

  • MSTN/激活素激活促进肌肉蛋白降解,增加CKD病残率和死亡率。
  • MSTN/激活素在血管壁的作用参与加速动脉粥样硬化和血管钙化。
  • 临床研究提示双重阻断ActRII受体可能比单靶点更有效。

临床怎么用

  • MSTN靶向治疗应作为体力活动和营养补充的辅助,而非替代。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The past two decades have witnessed tremendous progress in our understanding of the mechanisms underlying wasting and cachexia in chronic kidney disease (CKD) and in other chronic illnesses, such as cancer and heart failure. In all these conditions wasting is an effect of the activation of protein degradation in muscle, a response that increases the risk of morbidity and mortality. Major recent advances in our knowledge on how CKD and inflammation affect cellular signaling include the identification of the myostatin (MSTN)/activin system, and its related transcriptional program that promotes protein degradation. In addition, the identification of the role of MSTN/activin in the vascular wall shows premise that its inhibition can better control or prevent some effects of CKD on vessels, such as accelerated atherosclerosis and vascular calcifications. In this review, we summarize the expanding role of MSTN activation in promoting muscle atrophy and the recent clinical studies that investigated the efficacy of MSTN/activin pathway antagonism in sarcopenic patients. Moreover, we also review the utility of MSTN inhibition in the experimental models of CKD and its potential advantages in CKD patients. Lessons learned from clinical studies on MSTN antagonism in sarcopenic patients tell us that the anabolic intervention is likely better if we use a block of the two ActRII receptors. At the same time, however, it is becoming clear that MSTN-targeted therapies should not be seen as a substitute for physical activity and nutritional supplementation which are mandatory to successfully manage patients with wasting.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Verzola D, Barisione C, Picciotto D, et al. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease. Kidney Int. 2018. PMID: 30598193. doi:10.1016/j.kint.2018.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。